BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19942938)

  • 21. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Hasselblom S; Hansson U; Olsson M; Torén L; Bergström A; Nilsson-Ehle H; Andersson PO
    Br J Haematol; 2010 May; 149(4):560-8. PubMed ID: 20201946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mantle cell lymphoma in the ocular adnexal region.
    Looi A; Gascoyne RD; Chhanabhai M; Connors JM; Rootman J; White VA
    Ophthalmology; 2005 Jan; 112(1):114-9. PubMed ID: 15629830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.
    Imai H; Shimada K; Shimada S; Abe M; Okamoto M; Kitamura K; Kinoshita T; Shiraishi T; Nakamura S
    Pathol Int; 2009 Jul; 59(7):431-7. PubMed ID: 19563405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical characteristics, cell origin and prognosis of primary gastrointestinal diffuse large B-cell lymphoma: a report of 40 cases].
    Yang YL; Wang J; Zhao LZ; Gao ZF; Jing HM; Ke XY
    Ai Zheng; 2008 Jun; 27(6):636-41. PubMed ID: 18570740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions.
    Yoon JS; Ma KT; Kim SJ; Kook K; Lee SY
    Ophthalmic Plast Reconstr Surg; 2007; 23(2):94-9. PubMed ID: 17413620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
    Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
    Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
    Eser B; Sari I; Canoz O; Altuntas F; Cakmak E; Ozturk A; Ozkan M; Er O; Cetin M; Unal A
    Am J Hematol; 2006 May; 81(5):307-14. PubMed ID: 16628716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
    Grange F; Beylot-Barry M; Courville P; Maubec E; Bagot M; Vergier B; Souteyrand P; Machet L; Dalac S; Esteve E; Templier I; Delaporte E; Avril MF; Robert C; Dalle S; Laroche L; Delaunay M; Joly P; Wechsler J; Petrella T
    Arch Dermatol; 2007 Sep; 143(9):1144-50. PubMed ID: 17875875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy.
    Riihijärvi S; Taskinen M; Jerkeman M; Leppä S
    Eur J Haematol; 2011 Feb; 86(2):124-8. PubMed ID: 20942853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.
    Weisenburger DD; Anderson JR; Diebold J; Gascoyne RD; MacLennan KA; Müller-Hermelink HK; Nathwani BN; Ullrich F; Armitage JO
    Am J Hematol; 2001 Jul; 67(3):172-8. PubMed ID: 11391714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
    Tomita N; Motomura S; Hyo R; Takasaki H; Takemura S; Taguchi J; Fujisawa S; Ogawa K; Ishigatsubo Y; Takeuchi K
    Cancer; 2007 Mar; 109(6):1146-51. PubMed ID: 17311304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
    Gundrum JD; Mathiason MA; Moore DB; Go RS
    J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orbital lymphoproliferative tumors: analysis of clinical features and systemic involvement in 160 cases.
    Demirci H; Shields CL; Karatza EC; Shields JA
    Ophthalmology; 2008 Sep; 115(9):1626-31, 1631.e1-3. PubMed ID: 18440641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
    Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
    Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The differential diagnosis between primary cutaneous large B-cell lymphoma and cutaneous follicular lymphoma: prognostic and therapeutic implications.
    Fernandez-Flores A; Smucler-Simonovich A; Escalante F; Manjon JA
    Am J Dermatopathol; 2011 Dec; 33(8):819-26. PubMed ID: 22042259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.